Cadila Healthcare Ltd., an Indian drugmaker working to develop an indigenous coronavirus vaccine, said it expects to supply between 100 million to 150 million doses of its candidate this year.The Ahmedabad-based firm’s ZyCoV-D vaccine was approved to commence with final stage human trials in December, and it is recruiting 30,000 volunteers for its phase 3 tests, according to a presentation filed with India’s stock exchanges on Tuesday.Also Read | How plant meat is coming of age in IndiaCadila’s plasmid DNA candidate doesn’t use an infectious agent, like other vaccines, and instead introduces the DNA sequence encoding the antigen.India is preparing to launch its coronavirus inoculation campaign on Jan.